Fresenius SE KGaAXSWX:FRE 70 3-Year EBITDA Growth Rate is 6.50% as of Mar. 2026, which is 12% above its 10-year median of 5.80. GuruFocus rates XSWX:FRE with a GF Score™ of 70/100 and a GF Value™ of CHF32.58 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 531 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 57.06% on this metric.
During the past 12 months, Fresenius SE KGaA's average EBITDA Per Share Growth Rate was 3.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 6.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -14.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -7.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Fresenius SE KGaA was 42.90% per year. The lowest was -43.80% per year. And the median was 5.80% per year.
Fresenius SE KGaA (XSWX:FRE) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Fresenius SE KGaA 3-Year EBITDA Growth Rate Related Terms
XSWX:FRE vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's 3-Year EBITDA Growth Rate falls into.
Fresenius SE KGaA 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 6.50% mean?
Fresenius SE KGaA (XSWX:FRE) has a 3-Year EBITDA Growth Rate of 6.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fresenius SE KGaA and its competitors. This is 12% above median its historical median of 5.80. According to the industry distribution chart, Fresenius SE KGaA ranks #303 out of 531 companies in the Healthcare Providers & Services industry, placing it in the top 57.1%.
Is Fresenius SE KGaA's 3-Year EBITDA Growth Rate too high?
Fresenius SE KGaA's current 3-Year EBITDA Growth Rate of 6.50% is 12% above median its 10-year median of 5.80. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Fresenius SE KGaA's value of 6.50% is 34.3% below this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #303 out of 531 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #303 out of 531 companies for 3-Year EBITDA Growth Rate. This places Fresenius SE KGaA in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. Fresenius SE KGaA's value of 6.50% is 34.3% below this benchmark. While the company's 10-year median is 5.80 vs. the industry median of 9.90, Fresenius SE KGaA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 531 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current 3-Year EBITDA Growth Rate of 6.50% is 34.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current 3-Year EBITDA Growth Rate is 6.50%, which is 12% above median its own 10-year median of 5.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF32.58, compared to a current price of CHF37.79 — trading 16% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 6.50%, which is 12% above median its 10-year median of 5.80 and 34.3% below the Healthcare Providers & Services industry median of 9.90. Fresenius SE KGaA's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current 3-Year EBITDA Growth Rate is 6.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF37.79 is trading 16% above its estimated GF Value™ of CHF32.58.
GuruFocus considers Fresenius SE KGaA to be Modestly Overvalued.
Key valuation signals for XSWX:FRE:
3-Year EBITDA Growth Rate: 6.50% (12% above median its 10-year median of 5.80)
GF Value™: CHF32.58 vs. price of CHF37.79 (16% above fair value)
Industry Position: 34.3% below the Healthcare Providers & Services median (#303 of 531)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
70GF Score
Get the complete analysis for XSWX:FRE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 